Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
15 nov. 2023 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose...
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress
01 août 2023 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from ongoing clinical trials of investigational cancer immunotherapy PV-10 (rose bengal sodium) for...
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
01 déc. 2022 07h00 HE
|
Provectus Biopharmaceuticals Inc.
50% CR and 83% ORR by RECIST 1.1 criteriaRapid CRs achieved within 15 to 27 weeksMedian PFS not reached during 2-year treatment interval; 83% PFS rate100% OS rate for CRs; ongoing after 18 to 36...
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
10 nov. 2022 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer...
Provectus Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Single-Agent PV-10® in Stage III Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021
01 nov. 2021 08h00 HE
|
Provectus Biopharmaceuticals Inc.
184 patients: 44.9 months median overall survival774 PV-10-injected lesions (121 patients): 56% complete response KNOXVILLE, TN, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today...
Provectus Biopharmaceuticals Announces Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Treatment of Checkpoint-Refractory Advanced Cutaneous Melanoma at Society for Melanoma Research (SMR) 2021
28 oct. 2021 06h00 HE
|
Provectus Biopharmaceuticals Inc.
34.1 months median overall survival, 4.9 months median progression-free survivalBest overall response (RECIST 1.1): 5% CR, 26% ORR, 53% DCR (19 patients) KNOXVILLE, TN, Oct. 28, 2021 (GLOBE...
Provectus Biopharmaceuticals Provides Update on Research into Oral Administration of PV-10® Immunotherapy for Treatments of Hematology, Oncology, and Virology
04 oct. 2021 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on the Company’s research into the systemic administration of Provectus’ investigational...
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2021 Congress
27 sept. 2021 06h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from historical clinical trials and expanded access studies of investigational cancer...
FIRST STUDY OF QUALITY OF LIFE OF PATIENTS WITH LOCALLY ADVANCED CUTANEOUS MELANOMA PUBLISHED IN MELANOMA RESEARCH
27 déc. 2017 16h00 HE
|
Provectus Biopharmaceuticals Inc.
Emotional health/self-perception issues were most common; limitations of lifestyle and activities as well as coping strategies were also important Provectus Biopharmaceuticals expands pivotal Phase 3...